CD9: Differential expression of normal bone marrow cellular components and leukemic myeloid blasts

Area of Science:

• Hematology
• Immunophenotyping
• Leukemia Research

Background:

• CD9 expression is well-studied in B lymphoblastic leukemia but less so in acute myeloid leukemia (AML).
• Understanding CD9's role is crucial for differentiating normal myeloid progenitors from leukemic cells.

Purpose of the Study:

• Investigate CD9 expression in normal bone marrow cells and AML.
• Determine CD9's utility in distinguishing normal myeloid progenitors from abnormal ones in AML.

Main Methods:

• Flow cytometry was employed to quantify CD9 levels.
• Compared CD9 geometric mean fluorescence intensity and expression patterns across normal bone marrow subsets and AML subtypes.

Main Results:

• CD9 expression varied in normal cells, being lowest in mature B cells and myeloid blasts, intermediate in monocytes, and highest in hematogones.
• Hematopoietic stem cells (HSCs) showed higher CD9 expression than committed myeloid progenitors (CMPs).
• AML exhibited generally higher CD9 expression than normal myeloid blasts, with notable differential expression among AML subtypes, peaking in PML::RARA AML.

Conclusions:

• Aberrant CD9 expression is a valuable marker for differentiating normal from abnormal myeloid progenitors.
• CD9 expression levels are highest in acute myeloid leukemia with PML::RARA.
• Normal mature B cells can serve as an effective internal negative control for CD9 analysis.